Local production of soluble urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in the coronary circulation is associated with coronary endothelial dysfunction in humans

Michel T. Corban, Abhiram Prasad, Lisa Nesbitt, Darrell Loeffler, Joerg Herrmann, Lilach O. Lerman, Amir Lerman

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background-Soluble urokinase plasminogen activator receptor (suPAR) is a proinflammatory biomarker associated with immune activation and fibrinolysis inhibition. Plasminogen activator inhibitor (PAI-1) is associated with excessive fibrin accumulation, thrombus formation, and atherosclerosis. The relationship between cross-coronary suPAR and PAI-1 production and endothelial dysfunction remains unknown. Methods and Results-Seventy-nine patients (age 53±10 years, 75% women) with angina and normal coronary arteries or mild coronary artery disease (<40% stenosis) on angiogram underwent acetylcholine assessment of epicardial endothelial dysfunction (mid-left anterior descending coronary artery diameter decrease >20% after acetylcholine) and mircovascular endothelial dysfunction (coronary blood flow change <50% after acetylcholine). Simultaneous left main and coronary sinus suPAR and PAI-1 levels were measured in each patient before acetylcholine administration, and cross-coronary suPAR and PAI-1 production rates were calculated. Patients’ characteristics, except for age (51±10 versus 57±9, P=0.02), and resting coronary hemodynamics were not significantly different between patients with (26%) versus without (74%) epicardial endothelial dysfunction. Patients’ characteristics and resting coronary hemodynamics were not significantly different between those with (62%) and those without (38%) mircovascular endothelial dysfunction. Patients with mircovascular endothelial dysfunction demonstrated local coronary suPAR production versus suPAR extraction in patients with normal microvascular function (median 25.8 [interquartile range 121.6, –23.7] versus –12.7 [52.0, –74.8] ng/min, P=0.03). Patients with epicardial endothelial dysfunction had higher median coronary PAI-1 production rates compared with those with normal epicardial endothelial function (1224.7 [12 940.7, –1915.4] versus –187.4 [4444.7, –4535.8] ng/min, P=0.03). Conclusions-suPAR is released in coronary circulation of patients with mircovascular endothelial dysfunction and extracted in those with normal microvascular function. Cross-coronary PAI-1 release is higher in humans with epicardial endothelial dysfunction.

Original languageEnglish (US)
Article numbere009881
JournalJournal of the American Heart Association
Volume7
Issue number15
DOIs
StatePublished - Aug 1 2018

Keywords

  • Coronary circulation
  • Endothelial dysfunction
  • Epicardial
  • Microvascular dysfunction
  • Plasminogen activator
  • Soluble urokinase plasminogen activator receptor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Local production of soluble urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in the coronary circulation is associated with coronary endothelial dysfunction in humans'. Together they form a unique fingerprint.

  • Cite this